News

Jumping the gun on contralateral prophylactic mastectomy?


 

Rates of contralateral prophylactic mastectomy in breast cancer are on the rise, but are clinical indications always present to justify the procedure? Dr. Todd Tuttle discusses the trend and cautions physicians to provide patients with accurate assessments of cancer risk and the procedure's actual effects on life expectancy..

Recommended Reading

FDA advisory panel backs approval of neoadjuvant pertuzumab for breast cancer
MDedge Internal Medicine
Fear, anxiety drive contralateral mastectomy, survey finds
MDedge Internal Medicine
FDA approves first generic capecitabine
MDedge Internal Medicine
Keep your patents off my genes!
MDedge Internal Medicine
Breast cancer receptor change may predict outcomes
MDedge Internal Medicine
USPSTF breast cancer chemoprevention recommendations: We’re in this together
MDedge Internal Medicine
ASTRO outlines five radiation oncology practices that should be curtailed
MDedge Internal Medicine
Everolimus effective in women with early failure of adjuvant therapy
MDedge Internal Medicine
BMN 673 monotherapy makes splash in BRCA-mutated ovarian, breast cancer
MDedge Internal Medicine
False-negative rate for sentinel nodes high after neoadjuvant chemotherapy
MDedge Internal Medicine